6-Pyruvoyl-Tetrahydropterin Synthase Deficiency

VANCOUVER, British Columbia, July 05, 2023 (GLOBE NEWSWIRE) -- Mydecine Innovations Group Inc. ("Mydecine" or the "Company") (NEO:MYCO) (OTC:MYCOF) (FSE:0NFA), a biotechnology company engineering the next wave of innovative medications and treatment protocols to directly address mental health with a particular emphasis on addiction and PTSD, is pleased to announce the results of voting at its special meeting of shareholders which was held on Tuesday, July 4, 2023, by conference call (the “Meeting”). There were 15 shareholders represented in person or by proxy at the Meeting, holding 3,670,377 common shares, representing 14.72% of the Company’s total issued and outstanding common shares as of the record date for the Meeting. The voting results for the Meeting are set out below: Approval of the Re-Pricing of Debenture and Debenture Warrants The resolution to authorize and approve the re-pricing of the debenture and the debenture warrants was approved by a majority of votes cast by the disinterested shareholders who voted for the resolution present or represented by proxy at the Meeting. The re-pricing of the debenture and debenture warrants will be implemented at the discretion of the Board of Directors, should the Board of Directors believe that the adoption of the re-pricing of the debenture and debenture warrants is in the best interest of the Company. Voting results are set out below: Votes ForVotes Against#%#%3,644,28499.29%26,0930.71% Approval of Other Matters The resolution to transact such other business that may be brought properly before the Meeting and any adjournment or postponement of the Meeting. Voting results are set out below: Votes ForVotes Against#%#%3,646,22199.34%24,1560.66% About Mydecine Innovations Group, Inc. Mydecine Innovations Group is a publicly traded, pre-revenue biopharmaceutical company that began operations in North America and Europe in early 2020. Mydecine was founded to increase physicians' access to serotonin-modulating medicine. Recent research has demonstrated the therapeutic potential of psychedelic substances such as psilocybin and MDMA for treating intractable conditions such as pain, anxiety, depression, addiction, and PTSD, along with neurodegenerative disorders. Mydecine believes these compounds can be safer, more effective, and more accessible for patients and medical professionals through modern drug chemistry paired with artificial intelligence (AI). Mydecine is developing innovative medications for target indications with high mortality rates that have lacked innovation for decades and are controlled by dominant corporations. Mydecine developed several prodrug families, beginning with a psilocybin-derived smoking cessation drug undergoing a NIDA-funded trial at Johns Hopkins University. Mydecine is also developing MYCO-006—short-acting chemical analogs derived from MDMA for treating various conditions, including anxiety and pain. Mydecine utilizes cutting-edge artificial intelligence (AI) and pharma research infrastructure at the University of Alberta to develop and manufacture new medications to make them affordable and accessible to the general public upon Health Canada and FDA approval. The Mydecine team is enthusiastic about its mission and is dedicated to creating a positive difference in the lives of others. Learn more at https://www.mydecine.com. For more information, please contact: Media Contact:pr@mydecineinc.com Investor Relations:investorrelations@mydecineinc.com On behalf of the Board of Directors: Joshua Bartch, Chief Executive Officer contact@mydecineinc.com For further information about Mydecine Innovations Group, Inc., please visit the Company’s profile on SEDAR at www.sedar.com or the Company’s website at www.mydecine.com. This news release contains forward-looking information about Canadian securities laws regarding the Company and its business. It relates to future events or performance and reflects management’s expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as “expect,” “intends,” “anticipated,” “believes,” or variations (including negative variations) of such words and phrases or by stating that specific actions, events, or results “may,” "could," "would,” or “will” be taken, occur, or be achieved. This news release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of the common shares in any jurisdiction in which such an offer, solicitation, or sale would be unlawful before the registration or qualification under the securities laws of any such jurisdiction. Such forward-looking statements reflect management’s beliefs and are based on assumptions and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected, including, without limitation, risks regarding the COVID-19 pandemic, the availability and continuity of financing, the ability of the Company to protect and enforce its intellectual property adequately, the Company's ability to bring its products to commercial production, the continued growth of the global adaptive pathway medicine, natural health products, and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale, and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, other factors may cause effects not to be as anticipated, estimated, or intended. There can be no assurance that such information will be accurate, as actual results and future events could differ materially from those anticipated. These forward-looking statements are made as of the date hereof. The Company is not obligated to update or revise them to reflect new events or circumstances as required under applicable securities legislation.

CVN Launches Measurement-Based Care Training Toolkit Available to the Field at No-Cost STAMFORD, Conn., June 28, 2023 /PRNewswire/ -- Routine outcomes monitoring (ROM) and measurement-based care (MBC) have been shown to improve mental health outcomes. Yet, despite repeated calls for widespread adoption their use in clinical practice remains the exception within the U.S. mental health care system. Now, in Establishing Benchmarks for Outpatient Mental Health Care: A Call to Action with Consensus Recommendations, a new white paper released today, Cohen Veterans Network (CVN), a national not-for-profit network of mental health clinics for post-9/11 veterans, service members and their families, provides recommendations on how to best advance the use of standardized benchmarks and MBC throughout the field of mental health. "CVN is committed to advancing the field for all Americans as our nation faces unprecedented mental health challenges," says Cohen Veterans Network President & CEO Dr. Anthony Hassan. "We hope this white paper serves as a call to action for our colleagues across the field to mobilize around the use of standardized benchmarks. In doing so, we have an opportunity to improve treatment efficacy, support mental health parity and further transform the lives of the individuals we treat." The white paper captures key findings and recommendations from CVN's National Leadership Summit on Outpatient Mental Health Benchmarks held in October 2022 in Washington, D.C., during which a broad cross-section of leaders from across the mental health landscape convened to identify barriers and implementation challenges as well as actionable solutions related to the advancement of ROM and MBC. Findings from the summit and highlights from the white paper will be presented today in a webinar, Advancing the Field Through Behavioral Health Benchmarks: A Call to Action with Consensus Recommendations, at 12pm EDT hosted by Behavioral Health Business. Participants will learn about a range of recommendations from experts across the field in the areas of policy, practice, research, and training. "The consensus recommendations detailed in the white paper have been developed in collaboration with some of the best minds in the behavioral health field," says CVN-IQ Director Dr. David Linkh. "We are so thankful to all of our partners who joined us in this effort, and we are thrilled to be sharing our findings, which can significantly impact how we deliver mental health care in America." In conjunction with the release of the white paper, the network has launched the CVN Measurement-Based Care Training Toolkit, a comprehensive set of training materials designed to help mental health professionals incorporate measures to enhance the quality of care. It is available at no-cost. "Our MBC Training Toolkit has been thoughtfully designed to help clinicians within CVN and across the field of behavioral health incorporate measures into routine clinical care," says CVN Sr. Director of Clinical Practice and Training Dr. Stephanie Renno. "With the use of these assets, mental health professionals have an opportunity to enhance their clinical practice and further develop client-focused, customized care." Since its inception in 2016, CVN has treated more than 53,000 clients. The network provides evidence-based therapies to post-9/11 veterans, active duty service members and military family members through its 24 Steven A. Cohen Military Family Clinics across the country. Treatment is available for a wide variety of mental health challenges including depression, anxiety, adjustment issues, anger, PTSD, grief and loss, family issues, transition challenges, relationship concerns, and children's behavioral problems. Care is available in person or via CVN Telehealth, face-to-face video therapy. The white paper and executive summary can be found here. ABOUT COHEN VETERANS NETWORK Cohen Veterans Network (CVN) is a 501(c)(3) national not-for-profit philanthropic organization for post-9/11 veterans, active duty service members and their families. CVN focuses on improving mental health outcomes, operating a network of outpatient mental health clinics in high-need communities, in which trained clinicians deliver holistic evidence-based care to treat mental health conditions. It was established in 2016 by philanthropist Steven A. Cohen with a commitment of $275 million to build the network. Learn more about CVN at cohenveteransnetwork.org. SOURCE Cohen Veterans Network

With 25 years of law enforcement and regulatory experience, Triana joins Talkiatry equipped to navigate shifting state and federal regulations Triana will use his deep legal knowledge of the mental health space to work alongside Talkiatry's leadership team in supporting high-quality telepsychiatry care across the country NEW YORK, June 28, 2023 /PRNewswire/ -- Talkiatry, a leading provider of in-network psychiatric care and one of the largest employers of psychiatrists in the United States, today announced that Eric Triana has joined the team as Chief Compliance Officer. Triana will lead Talkiatry's compliance efforts across federal- and state-level laws as the national psychiatry practice works to increase quality mental health care access across the country. The United States is in the middle of a mental health crisis. 122 million people, or 37% of the country, live in areas lacking enough mental health professionals to meet demand. To address the issue, telepsychiatry practices have increased access to treatment for vulnerable populations with their flexibility and convenience untethered from location. People living in mental health deserts or rural areas are just a few examples of those who have benefited from virtual mental health care. But with increased access comes increased oversight. Virtual psychiatry finds itself in constant regulatory flux, navigating a complex web of laws to protect patients and remain compliant. While the DEA has dominated recent headlines by extending the current rules regarding the prescribing of controlled substances via virtual appointments, this is just a sliver of the telepsychiatry legal landscape. Federal and state-by-state licensing rules can complicate how care is delivered depending on where patients live, while ever-evolving technology means that remaining HIPAA-compliant and protecting patient privacy becomes a moving target. Triana understands the importance of these rules on a personal and professional level. He has also seen the positive impact virtual mental health care can have on families, having watched members of his family benefit from increased access to psychiatric treatment. In retiring from the DEA, he followed his passion for increasing access to quality mental health care to work with leading telepsychiatry provider Talkiatry. "It's more complicated than ever to parse the regulations governing telepsychiatry, including licensing requirements, technology laws, patient access guidelines, and rules surrounding the prescribing of controlled substances. That's why it's so important to have Eric on board leading our compliance efforts," said Robert Krayn, CEO and cofounder of Talkiatry. "His years of experience at the top levels of law enforcement mean he understands the landscape better than anyone, and will ensure our team maintains compliance with state and federal laws, even as they rapidly change." Triana was employed at the Drug Enforcement Administration in a number of positions for more than two decades before joining Talkiatry. He is recognized for his expertise on pharmaceutical compliance and investigations in the U.S., and for the last 13 years worked in multiple Diversion Control Program positions as part of the DEA's regulatory division. As a DEA Diversion Control Division Deputy Assistant Administrator (his final DEA role from which he retired in March 2023), Triana provided enforcement direction and supervised all of the DEA's regulatory criminal, civil, and administrative licensure operations involving pharmaceutical controlled drugs and List chemicals in the U.S. During his time at the DEA, Triana designed programs to identify and detect those in the healthcare industry who violated U.S. and state healthcare laws, including the federal Controlled Substance Act, Anti-Kickback Statute, and False Claims Act. He was directly involved in healthcare investigations which resulted in criminal, civil, and administrative sanctions by HHS and DEA to include exclusion of Medicare and the suspension or revocation of registrations (licenses), as well as state medical licenses. Triana worked joint investigations with various federal and state agencies including HHS, FBI, United States Attorney's Offices, DOJ Main Justice Healthcare Fraud Section, New York State Department of Financial Services, New York State Medicaid Fraud Control Unit, and more. Before joining the DEA, Triana was a police officer and detective for the Baltimore City Police Department, as well as an accountant and auditor for an accounting firm. He has a B.S. in Accounting from Rutgers University and a J.D. from Seton Hall School of Law. Triana is also a member of the New Jersey and New York State Bar Associations and is a Certified Fraud Examiner. "Telepsychiatry has completely changed mental health care in this country, and Talkiatry is at the forefront of bringing access to populations who were previously ignored," said Triana. "With my decades of compliance and regulatory experience, I will ensure that Talkiatry's psychiatrists are always informed and supported in a constantly changing world with confusing and often conflicting information, so they can focus on delivering high-quality support to people across the U.S." Talkiatry is one of the nation's largest mental health practices. With its focus on virtual care, Talkiatry's mission is to eliminate barriers that prevent people from accessing quality psychiatric support. This means providing psychiatry services that are covered by more than 60 health insurance plans, while making sure new patients can be seen within days of booking an initial appointment. Talkiatry patients can expect 60-minute first visits and 30-minute follow-ups and will see the same psychiatrist for every appointment. Talkiatry's team of more than 300 psychiatrists specializes in treating mental health conditions including anxiety, depression, PTSD, and more. About Talkiatry Talkiatry is a national mental health practice that provides in-network psychiatry and therapy. They were co-founded by a patient and a triple-board-certified psychiatrist to solve the problems both groups face in accessing and providing the highest quality mental healthcare. 60% of adults in the U.S. with a diagnosable mental illness go untreated every year because care is inaccessible, while 45% of clinicians are out of network with insurers because reimbursement rates are low and paperwork is unduly burdensome. With innovative technology and a human-centered philosophy, Talkiatry provides patients with the care they need—and allows psychiatrists to focus on why they got into medicine. Learn more at and follow us on Instagram, Facebook, and LinkedIn. Media Contact [email protected] SOURCE Talkiatry